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Lysophosphatidic acid (LPA), a naturally occurring bioactive phospholipid, mediates a multitude of
(patho)physiological events including activation of mitogen-activated protein kinases (MAPKs). As LPA
may induce cellular reponses in human osteosarcoma, the present study aimed at investigating
expression of various LPA receptors, LPA-mediated activation of MAPK via G-protein coupling, and
expression of early response genes in a cellular model for human osteosarcoma. We show that MG-63
cells express three members of the endothelial differentiation gene (Edg) family of G-protein coupled
receptor transcripts (LPA1e3) but only two (LPA4/5) out of three members of the non-Edg family LPA
receptor transcripts. Stimulation of MG-63 cells with LPA or synthetic LPA receptor agonists resulted
in p42/44 MAPK phosphorylation via LPA1eLPA3 receptors. Using pharmacological inhibitors, we
show that LPA-mediated phosphorylation of p42/44 MAPK by LPA receptor engagement is transmitted by
Gai-dependent pathways through the Src family of tyrosine kinases. As a consequence, a rapid and
transient upregulation of the zinc ﬁnger transcription factor early growth response-1 (Egr-1) was
observed. Egr-1 expression was strictly mediated via Gai/Src/p42/44 MAPK pathway; no involvement of
the Gaq/11/PLC/PKC or the PLD/PI3 kinase/Akt pathways was found. LPA-induced expression of functional
Egr-1 in MG-63 cells could be conﬁrmed by electrophoretic mobility shift assay. LPA-induced Egr-1
upregulation was accompanied by a time-dependent decrease of periostin (previously called osteoblast-
speciﬁc factor 2), a cell adhesion protein for pre-osteoblasts. Silencing of LPA1 and/or Egr-1 in MG-63 cells
reversed LPA-mediated suppression of periostin. We here demonstrate a crosslink between Egr-1 and
periostin in cancer cells, in particular in human osteosarcoma.
 2012 Elsevier Masson SAS. Open access under CC BY-NC-ND license.1. Introduction
Human osteosarcoma represents the most common non-
hematologic malignant tumour of bone [1]. Osteosarcoma coin-
cides with a period of rapid bone growth suggesting a correlation
between bone growth and development of this tumour. Like all
sarcomas in young patients, osteosarcoma begins to metastasize
very early in its development. Recent investigations exhibited that
human osteosarcomas are characterized by a variety of generic
alterations resulting in inactivation of numerous tumour
suppressor genes and overexpression of oncogenes [2]. Many
osteosarcomas appear to harbour genetic lesions, such as INK4Aax: þ43 316 385 3300.
z.at (W. Windischhofer).
nder CC BY-NC-ND license.deletion [3], that inactivate both, retinoblastoma and p53 pathways
leading to dysfunction of cell cycle control. Oncogenes unrelated to
retinoblastoma and p53 pathways, e.g. Myc [4] are overexpressed
or activated in a proportion of osteosarcoma.
Lysophosphatidic acid (LPA), a naturally occurring phospholipid,
mediates a multitude of (patho)physiological events [5]. LPA
induces growth-factor-like responses, e.g. cell proliferation,
survival and migration in most normal and transformed cell types
which are concordant with many of the “hallmarks of cancer” [6].
At the cellular level, LPA-inducedmetabolic responses aremediated
via G-protein coupled receptors and the broad spectrum of cellular
and biological actions of LPA is achieved by engagement of LPA
receptor subtypes 1e6 (LPA1e6). While LPA1eLPA3 represent
members of the endothelial differentiation gene (Edg) family of
G-protein coupled receptors, LPA4e6 are members of the non-Edg
W. Windischhofer et al. / Biochimie 94 (2012) 1997e20051998family of LPA receptors [7,8]. The most widely expressed LPA
receptor subtype is LPA1 [9] and functional importance has been
demonstrated in lpa1/ mice, which show weight loss and
neonatal mortality [10]. Compared to LPA1, LPA2 and LPA3 exhibit
restricted distribution but are suggested to contribute to the
pathophysiology of cancer [11e15]. LPA4 and LPA5 are expressed at
low levels in most tissues [16,17].
Themajor signalling cascades evoked by LPA are (i) Gq-mediated
activation of phospholipase C (PLC) leading to Ca2þ mobilization,
(ii) Gai-mediated inhibition of adenylate cyclase, activation of
mitogen-activated protein kinase (MAPK) pathway(s) and protein
kinase B (PKB)/Akt pathway or (iii) Ga12/13-mediated activation of
RhoA [18,19]. Activation of these pathway(s) deﬁnes speciﬁc
cellular responses such as proliferation, migration and gene tran-
scription, including expression of early growth response-1 (Egr-1)
[20,21]. Egr-1 belongs to the group of early response genes, being
expressed rapidly after stimulation with growth factors, hormones
and neurotransmitters and has been shown to play important roles
in bone formation [22]. Furthermore, Egr-1 is thought to be
a convergence point to couple extracellular signals to long-term
responses by altering gene expression of Egr-1 target genes such
as c-Myc, c-Fos and growth factor receptors, respectively [23].
The aim of the present study was to investigate expression of
various LPA receptors as well as LPA-mediated G-protein coupled
downstream signalling in humanMG-63 osteosarcoma cells. MAPK
cascades are key signalling pathways involved in the regulation of
normal cell proliferation, and aberrant regulation of the MAPK
cascade contributes to induction of early response genes in cancer
[24]. MAPKs include three different pathways where the extracel-
lular signal regulated protein kinases (also known as p42/44MAPK)
have been the subject of intense research scrutiny [25]. We were
interested whether LPA-induced signal transduction pathway(s)
occurs via the MAPK cascade and may lead to functional expression
of Egr-1 as a basis for its involvement in bone biology. We
demonstrate that LPA stimulates rapid and transient synthesis of
Egr-1 on mRNA and protein level via G-proteins of the Gai subtype.
This activation is dependent on p42/44 MAPK while no alterations
of certain growth factor receptors were found [26]. Finally, we show
that Egr-1 inhibits the expression of the extracellular matrix
protein periostin in human MG-63 osteosarcoma cells in response
to LPA-induced signalling cascades.
2. Materials and methods
2.1. Reagents
Foetal calf serum (FCS) and trypsin/EDTA were from PAA (Linz,
Austria). Gentamycin, a-minimum essential medium (a-MEM),
NuPAGE 10% Bis-Tris Gels, NuPAGE MES SDS running buffer,
NuPAGE LDS sample buffer, NuPAGE sample reducing agent,
SeeBlue Plus prestained standard, nitrocellulose membranes
(0.45 mm pore size) and DNase-I were from Gibco Invitrogen (Lofer,
Austria). LPA (1-oleoyl-2-hydroxy-sn-glycero-3-phosphate) was
fromAvanti Polar Lipids (Alabaster, AL, USA). Pertussis toxin (PTX),
manumycin A, (S)-1-oleoyl-2-O-methyl-glycerophosphothionate
triethylammonium salt (OMPT), N-palmitoyl-L-serine phosphoric
acid (L-NASPA), and Ki16425 were from SigmaeAldrich (Vienna,
Austria). Gö6983, LY294002, PD98059, SQ22536, SB203580, JNK
inhibitor II, PP2, Akt inhibitor, tyrphostins (AG1295, AG183,
AG1478) and toxin B were from Calbiochem (La Jolla, CA, USA).
U73122, propranolol, dodecylphosphate (DDP) and rp-cAMPS were
from Biomol (Hamburg, Germany). Cell permeable Rho inhibitor
exoenzyme C3 transferase was from Cytoskeleton (Denver, CO,
USA). BCA protein assay, SuperSignal West Pico chemilumines-
cent substrate and NE-PER nuclear and cytoplasmic proteinextraction kit were from Pierce Biotechnology (Rockford, IL, USA).
Complete Mini protease inhibitor cocktail tablets were from Roche
Applied Science (Vienna, Austria). Hyperﬁlm MP and [g-32P]
ATP (3000 Ci/mmol) were from GE Healthcare (Vienna,
Austria). QIAGEN OneStep RT-PCR kit and RNeasy RNA puriﬁca-
tion kit were from QIAGEN (Hilden, Germany). All primer pairs
(Supplement, Table I) were from TibMolBiol (Berlin, Germany).
2.2. Cell culture
The human osteosarcoma cell line MG-63 (ATCC, Manassas, VA,
USA) was maintained in a-MEM, supplemented with 5% (v/v) FCS,
50 mg/ml (w/v) gentamycin and 2 mM L-glutamine (37 C, humid-
iﬁed atmosphere of 5% CO2). Cells were used between 10th
and 20th passage counted from the day of receipt. Cells were
cultured in 75 cm2 tissue culture ﬂasks and seeded prior to treat-
ment in six-well plates (Corning Incorporated, New York, NY, USA)
at a seeding density of 10,000 cells/cm2 in a ﬁnal volume of 4 ml
a-MEM. After 3 days, the medium was changed to 4 ml of fresh
a-MEM (with FCS) and experiments were performed on day 6.
2.3. Cell culture experiments
For time-dependent activation of the p42/44 MAPK pathway,
cells were incubated up to 45 min in medium containing indicated
LPA concentrations. Time-dependent expression of early response
genes was performed by stimulation of cells up to 3 h (mRNA
expression) and 6 h (protein expression). For concentration-
dependent activation of p42/44 MAPK, the cells were incubated
inmedium containing either subtype-speciﬁc LPA receptor agonists
(L-NASPA, DDP, OMPT) or LPA at indicated concentrations for 5 min.
Investigating signal transduction pathways, cells were incubated
for 30 min in medium containing the LPA receptor antagonist
Ki16425 (10 mM) and/or various inhibitors of signal transduction:
manumycin A (10 mM), Gö6983 (500 nM), PD98059 (25 mM),
SB203580 (10 mM), JNK inhibitor II (1 mM) PP2 (10 mM), U73122
(10 mM), propranolol (100 mM), SQ22536 (25 mM), rp-cAMPS
(25 mM), LY294002 (25 mM), Akt inhibitor (25 mM), tyrphostins
AG1478, AG183, and AG1295 (all at 10 mM); PTX (100 ng/ml), cell
permeable C3 transferase (5 mg/ml) and toxin B (100 ng/ml) were
used as inhibitors of G-protein signalling. All signal transduction
inhibitors [27] were dissolved according to manufacturer’s
suggestions.
2.4. Protein isolation and Western blot analysis
Conﬂuent cells were treated as indicated by addition of various
pharmacological agonists or antagonists directly into the medium.
Experiments were terminated by aspiration of the medium and
cells were washed twice with chilled PBS (pH 7.4). Cell lysis was
performed on ice for 10 minwith 100 ml lysis buffer (HEPES 50 mM,
NaCl 150 mM, EDTA 1 mM, Na4P2O7 10 mM, Na3VO4 2 mM, NaF
10 mM, Triton X-100 1% (v/v), glycerol 10% (v/v), Complete Mini
protease inhibitor; pH 7.4). Insoluble cell debris was removed by
centrifugation at 11,000 g (4 C; 10 min). Protein content of cell
lysates was determined using the BCA protein assay according to
the manufacturer’s suggestions. Aliquots of cell lysates (25e50 mg
protein) were diluted with an equal volume of NuPAGE LDS
sample buffer and supplemented with NuPAGE sample reducing
agent (5% [v/v]). After heating for 10 min at 70 C samples were
subjected to electrophoresis on 4e12% gradient SDS-PAGE gels.
Proteins were transferred to nitrocellulose membranes (2 h, 80 V).
The following primary antibodies were used: (i) mousemonoclonal
anti-phosphorylated p42/44 (pp42/44) MAPK (dilution 1:1000, Cell
Signaling Technology, Beverly, MA, USA); (ii) rabbit polyclonal anti-
Fig. 1. RT-PCR of LPA receptors in human MG-63 cells: cells were cultured in a-MEM
until conﬂuence, RNA was isolated and LPA1e5 receptor transcripts were ampliﬁed by
RT-PCR using speciﬁc forward and reverse oligonucleotide primer pairs (Supplement,
Table I). The corresponding RT-PCR products were separated on 1.5% agarose gels.
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Santa-Cruz, CA, USA); (iii) rabbit polyclonal anti-periostin (clone
H-300, dilution 1:2000, Pierce Biotechnology, Rockford, IL, USA);
(iv) rabbit polyclonal anti-epidermal growth factor receptor (EGFR,
clone 1005, dilution 1:1000, Santa Cruz Biotechnology); (v) rabbit
polyclonal anti-platelet derived growth factor receptor a (PDGFRa,
clone C-20, dilution 1:1000, Santa Cruz Biotechnology); (vi) and
rabbit polyclonal anti-PDGFRb (clone P-20, dilution 1:1000, Santa
Cruz Biotechnology). Detection of immunoreactive bands was
performed with horse-radish-peroxidase (HRP)-conjugated goat
anti-mouse IgG (dilution 1:10,000, Rockland, Gilbertsville, PA, USA)
or HRP-conjugated goat anti-rabbit IgG (dilution 1:10,000, Jackson
ImmunoResearch Laboratories, Inc., Austria) followed by incuba-
tion with the SuperSignalWest Pico chemiluminescent substrate.
For normalization, the membranes were stripped (using an anti-
body stripping buffer [Gene Bio Application, Kfar Hanagid, Israel])
and reprobed with rabbit polyclonal anti-p42/44 MAPK (anti-ERK-
1, clone K-23, dilution 1:1000) or mouse monoclonal anti-b-actin
(clone C4, dilution 1:1000, Santa Cruz Biotechnology) as primary
antibodies [28].
2.5. RNA isolation and reverse transcriptase polymerase chain
reaction (RT-PCR)
Cells were cultured in 6-well plates and no medium exchange
was performed within 60 h prior to the experiments. After
reaching conﬂuence, cells were treated as indicated and washed
twice with PBS (pH 7.4). Total RNA was extracted using RNeasy
RNA puriﬁcation kit, treated with DNase-I and RNA content was
determined by measuring the absorbance at 260 nm. RT-PCR was
performed with QIAGEN OneStep RT-PCR kit according to the
manufacturer’s suggestions including 100 ng template RNA and
gene-speciﬁc primers at ﬁnal concentrations of 0.6 mM. The
reverse transcription reaction was performed at 42 C for 1 h,
followed by an initial PCR activation step for 15 min at 95 C, 10 s
at 94 C, 30 s at indicated annealing temperature (Supplement,
Table I), 30 s at 72 C and a ﬁnal elongation at 72 C for 7 min.
Primer sequences, annealing temperatures, number of ampliﬁca-
tion cycles and amplicon size for each RT-PCR are listed in
Supplement, Table I. RT-PCR products were separated on 1.5%
agarose gels supplemented with 0.1% (v/v) ethidium bromide and
visualised using a UV transilluminator (Herolab; Heidelberg,
Germany). To ensure equal RNA loading, RT-PCR for glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) was performed for
each experiment [29,30].
2.6. Electrophoretic mobility shift assay (EMSA)
Conﬂuent cells were treated as indicated above. Reactions were
terminated by aspiration of the medium. Cells were washed twice
with chilled PBS (pH 7.4), harvested by scraping with a rubber
scraper and pelleted by centrifugation at 500 g (4 C; 3 min). Non-
denatured, active nuclear proteins were isolated using NE-PER
extraction reagents including Complete Mini protease inhibitors
according to the manufacturer’s suggestions. Protein concentra-
tions were determined using the BCA protein assay kit. Nuclear
extracts were aliquoted and stored at 70 C until use. Nucleotide
sequences of the oligonucleotides containing an Egr-1 consensus
binding sequence as reported by Santa Cruz Biotechnology
(SC-2529) are 50-GGATCCAGCGGGGGCGAGCGGGGGCGA-30 and 30-
CCTAGGTCGCCCCCGCTCGCCCCCGCT-50. Complementary oligonu-
cleotides were annealed to form double-stranded DNA followed by
radioactive labelling with [g-32P]ATP using T4 Polynucleotide
kinase and removal of non-incorporated nucleotides via Micro
Bio-Spin-6 Chromatography Columns [31]. To perform EMSAbinding reaction, 5 mg of nuclear extracts were incubated (10 min,
25 C) with binding buffer (10 mM Tris, 50 mM NaCl, 1 mM
dithiothreitol, 0.1 mM EDTA, 5% (v/v) glycerol, pH 7.5) containing
0.25 mg poly [d(IeC)] and 5 mg bovine serum albumin. Labelled
oligonucleotides were added to each reaction mixture and incu-
bated for 20 min at 25 C. After addition of glycerol to a ﬁnal
concentration of 20% (v/v), samples were separated by electro-
phoresis on a 3.9% PAGE (acrylamide:bisacrylamide, 29:1, v/v) in
22.5 mM Tris boric acid buffer (0.5 mM EDTA, pH 8.3) at 25 C
(3.5 h, 120 V). The gel was dried under vacuum (80 C, 1.5 h) and
exposed to Hyperﬁlm MP Film for 12e24 h. For competition
experiments, one ml of non-radiolabelled Egr-1 oligonucleotides
(20-fold molar excess) was added to the binding mixture before
addition of the radiolabelled probe.2.7. siRNA experiments
MG-63 cells were transfected with siRNAs speciﬁc for Egr-1
(catalogue number: SI00030709, Qiagen) or LPA1 (Edg-2, Santa
Cruz: catalogue number: sc-43746) or with a scrambled negative
control siRNA (catalogue number: 1022076, Qiagen). The siRNA
transfection was performed with oligofectamine (Invitrogen)
according to the manufacturer’s suggestions. Brieﬂy, cells were
plated at a density of 5  104 in 6-well plates and grown overnight
to 40e60% conﬂuence. Cells were transfected in 1 ml MEMwithout
FCS containing 4 ml of oligofectamine and 50 nM of the respective
siRNA. As a mock control, cells were treated with the transfection
reagent alone [32]. After an incubation period of 6 h at 37 C
(5% CO2), the transfection mix was removed and replaced by the
standard growth medium (MEM, 5% FCS). Then, cells were culti-
vated for further 66 h followed by stimulation with indicated LPA
concentrations. After indicated time periods total cell protein was
isolated to determine the expression level of Egr-1, periostin and
b-actin using speciﬁc antibodies.
All experiments listed above were performed at least three
times.3. Results
3.1. LPA receptor subtypes in human MG-63 cells
To identify LPA receptor subtypes, speciﬁc primer pairs were
used (Supplement, Table I). After RT-PCR analysis, separating and
sequencing of the corresponding PCR products, we show that
transcripts for LPA1e5 are expressed in MG-63 cells (Fig. 1). No
transcripts for the recently identiﬁed LPA6 (P2Y5 [33,34]) were
found under our experimental conditions (data not shown).
Fig. 3. Western blot of LPA-induced phosphorylation of p42/44 MAPK in human MG-
63 cells in the presence of bacterial toxins or pharmacological inhibitors: cells were
incubated overnight with (A) PTX (200 ng/ml), C3 exoenzyme (5 mg/ml), toxin B
(100 ng/ml) for 15 minwith (B) Ki16425 (10 mM), SQ22536 (25 mM), rp-cAMPS (25 mM),
PP2 (10 mM) and for (C) 15 min with PD98059 (25 mM), SB203580 (25 mM), JNK
inhibitor II (1 mM) before stimulation with 20 mM LPA for 5 min. Cells were lysed,
aliquots of protein lysates were subjected to SDS-PAGE and immunoreactive phos-
phorylated and total p42/44 MAPK bands were detected as described in Fig. 2;
(blank ¼ non stimulated cells; control ¼ cells stimulated with 20 mM LPA).
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As LPA receptor signallingmay be coupled withMAPK activation
in cancer cells, we investigated the involvement of endogenously
expressed LPA receptor subtypes in MG-63 cells. Due to the lack of
commercially available speciﬁc agonists for LPA4e5, only members
of the Edg family were tested. Concentration-dependent activation
of MG-63 cells with different LPA-receptor agonists revealed
pronounced phosphorylation of p42/44 MAPKs with L-NASPA
(LPA1) and OMPT (LPA3) while the effect of DDP (an LPA2 agonist) on
p42/44MAPK phosphorylationwas less pronounced (Fig. 2A). From
these experiments, we conclude that preferentially LPA1 and LPA3
are operative to promote phosphorylation of p42/44 MAPK.
Naturally occurring LPA is effective to promote phosphorylation
of p42/44 MAPK at comparable concentrations as shown for the
synthetic agonists L-NASPA and OMPT (Fig. 2A). Therefore, LPA was
used as an agonist in all ongoing experiments. Time-dependent
stimulation of MG-63 cells with LPA resulted in a rapid and tran-
sient phosphorylation of p42/44 MAPK, reaching a maximum
activation at approx. 5 min after stimulation (Fig. 2B). Fig. 2C shows
that phosphorylation of p42/44 MAPK in response to LPA is
concentration-dependent.
3.3. Activation of the MAPK pathway in human MG-63 cells via
Gai-protein
Next, speciﬁc toxins were used to reveal the G-protein coupling
involved in LPA-mediated p42/44 MAPK phosphorylation. PTX
(known to directly inactivate the Gai subunit of heterotrimeric type
of G-proteins) completely inhibited LPA-induced p42/44 MAPK
phosphorylation (Fig. 3A). To investigate a putative role for small
monomeric G-proteins downstream of Gai, cell permeable C3
exoenzyme (inhibiting the Rho family of small G proteins) and toxin
B (inhibiting in addition small GTPases such as Rac and Cdc42) were
used. No involvement of these small monomeric G-proteins in
LPA-mediated p42/44 MAPK phosphorylation was found (Fig. 3A).
To study signalling events downstream of Gai, MG-63 cells were
pretreated with various inhibitors of key molecules in signal
transduction pathway(s). The LPA receptor antagonist Ki16425 [35]
completely inhibited p42/44 phosphorylation indicating that
stimulation of this MAPK pathway is speciﬁcally related to LPA
receptor activation (Fig. 3B). Involvement of the PKA pathway could
be excluded as neither SQ22536 (an inhibitor of adenylate cyclase)
nor rp-cAMPS (a cAMP antagonist) impaired p42/44 MAPKFig. 2. Western blot of LPA- and synthetic LPA receptor agonist-induced concentration- or ti
stimulated for 5 min with L-NASPA (LPA1), DDP (LPA2) and OMPT (LPA3) at indicated concent
LPA]). (BeC) cells were incubated in medium containing (B) 20 mM LPA for indicated time pe
protein lysates were subjected to SDS-PAGE and transferred to nitrocellulose. Phospho-spec
For normalization, membranes were stripped and reprobed with rabbit anti-p42/44 (dilut
antibodies (dilution 1:10,000) using the Super signal system.phosphorylation (Fig. 3B). Next, a possible involvement of the Src
family of proteins was tested. These non-receptor tyrosine kinases
can be activated by G-protein-mediated activation of PKC as well as
by growth factor receptor-mediated signalling. PP2, a speciﬁc Src
inhibitor, completely blunted phosphorylation of p42/44 MAPK
(Fig. 3B). In contrast to Src, inactivation of the likely downstream
effector Ras by manumycin A did not impair LPA-induced p42/44
MAPK phosphorylation (Supplement Fig. IA) indicating that Ras is
not involved.
To further investigate involvement of Gaq/11-mediated signal-
ling, MG-63 cells were pre-treated with U73122 or Gö6983. As
these inhibitors did not impair LPA-induced phosphorylation of
p42/44 MAPK, activation via PLC and PKC can further be excluded
(Supplement Fig. IB). Propranolol and LY294002 (Supplement
Fig. IB) as well as the Akt inhibitor (Supplement Fig. IA) had also
no effect on p42/44 MAPK phosphorylation, the PLD/PI3 kinase/Akt
axis is obviously also not involved in LPA-mediated activation of
p42/44 MAPK in MG-63 cells.
As PKC is not contributing to p42/44 MAPK phosphorylation
(Supplement Fig. IB), a possible involvement of Src induction via
transactivation of growth factor receptor tyrosine kinases was
tested. Treatment of MG-63 cells with tyrphostins AG183 and
AG1478 (two inhibitors of the EGFR) and AG1295 (an inhibitor of
the PDGFR) had no effect (Supplement, Fig. II); this indicates that
transactivation of EGFR and/or the PDGFR is not operative in LPA-me-dependent phosphorylation of p42/44 MAPK in human MG-63 cells: (A) cells were
rations (b ¼ blank [non-stimulated cells], c ¼ control [cells were stimulated with 20 mM
riods or with (C) indicated concentrations of LPA for 5 min. Cells were lysed, aliquots of
iﬁc mouse monoclonal anti-p42/44 (dilution 1:1000) was used as a primary antibody.
ion 1:1000). Immunoreactive bands were visualized with HRP-conjugated secondary
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MG-63 cells with LPA isolation of RNA and subsequent RT-PCR
analysis for EGFR and PDGFRa/b revealed that LPA treatment did
not alter expression of these receptors on mRNA level (Supplement
Fig. IIIA). These ﬁndings were parallelled on the protein level when
cells were incubated with LPA up to 6 h (Supplement Fig. IIIB).
To conﬁrm that LPA speciﬁcally activates the p42/44 MAPK
cascade, different inhibitors of the MAPK pathway were used. As
expected SB203580 (inhibitor of p38MAPK) and the JNK inhibitor II
(inhibitor of SAPK/JNK) had no inhibitory effect on LPA-induced
p42/44 MAPK phosphorylation. In contrast, PD98059 (an inhib-
itor of the MAPK kinase upstream of p42/44) completely abrogated
immunoreactive pp42/44 signal (Fig. 3C).Fig. 5. RT-PCR and Western blot of LPA-induced expression of Egr-1 in human MG-63
cells: cells were incubated overnight with (A) PTX (200 ng/ml), C3 exoenzyme (5 mg/
ml), toxin B (100 ng/ml) or (B) for 15 min with Ki16425 (10 mM), SQ22536 (25 mM), rp-
cAMPS (25 mM), PP2 (10 mM) or (C) for 15 min with PD98059 (25 mM), SB203580
(25 mM), JNK inhibitor II (1 mM) followed by stimulation with 20 mM LPA for 30 min
(mRNA) or 2 h (protein). Upper panel: RNA was isolated and ampliﬁcation was per-
formed by RT-PCR using speciﬁc forward and reverse oligonucleotide primer pairs. PCR
products were separated on 1.5% agarose gels. To ensure equal gel loading, control
GAPDH RT-PCR was performed. Lower panel: the cells were lysed and aliquots of
protein lysates were subjected to SDS-PAGE and transferred to nitrocellulose as
described in Materials and methods. Rabbit polyclonal anti-Egr-1 (dilution 1:1000)
was used as a primary antibody. For normalization, the membranes were stripped and
reprobed with mouse monoclonal anti-b-actin (dilution 1:1000); (blank ¼ non stim-
ulated cells; control ¼ cells stimulated with 20 mM LPA).3.4. Gai and p42/44 MAPK-dependent functional expression of Egr-1
in human MG-63 cells
Stimulation of the p42/44 MAPK pathway may result in
a multitude of events, including expression of early response genes
e.g. proto-oncogenes c-Myc and Egr-1. We here show that c-Myc on
mRNA level is constitutively expressed in MG-63 cells in response
to LPA (Fig. 4A). In contrast, LPA induced a rapid and transient
expression of Egr-1 on mRNA level reaching a maximum after
30 min; Egr-1 mRNA levels declined to basal levels after 120 min
(Fig. 4A). Time-dependent expression of Egr-1 on the protein level
revealed maximum expression in between 1 and 3 h after LPA
stimulation (Fig. 4B).
Next, MG-63 cells were preincubated with bacterial toxins or
other inhibitors prior to LPA stimulation and both RT-PCR (Fig. 5,
upper panel) andWestern blot experiments were performed (Fig. 5,
lower panel). The cell permeable C3 and toxin B had no effect while
decreased Egr-1 expression was found in PTX-treated cells. These
ﬁndings suggest involvement of Gai but not of small GTPases (Rho,
Rac and Cdc42) in LPA-induced Egr-1 expression. The LPA receptor
antagonist Ki16425 and the Src kinase inhibitor PP2 impair Egr-1
expression on mRNA and protein level in response to LPA while
SQ22536 and rp-cAMPS had no effect (Fig. 5B). All other inhibitorsFig. 4. LPA-induced time-dependent expression of early response genes in human
osteosarcoma cells: time-dependent expression of (A) c-Myc and Egr-1 on mRNA level
and (B) Egr-1 on protein level after stimulation of MG-63 cells with 20 mM LPA at
indicated time periods. RNA was isolated and ampliﬁcation was performed by RT-PCR
using speciﬁc forward and reverse oligonucleotide primer pairs (Supplement, Table I).
PCR products were separated on 1.5% agarose gels. To ensure equal gel loading, control
GAPDH RT-PCR was performed. (B) For Western blot experiments, cells were lysed,
protein aliquots were subjected to SDS-PAGE and transferred to nitrocellulose. Rabbit
polyclonal anti-Egr-1 (dilution 1:1000) was used as a primary antibody. Normalization
was performed with mouse monoclonal anti-b-actin (dilution 1:1000).(as already mentioned in Supplement Fig. I) failed to alter Egr-1
expression (Supplement Fig. IVAeD). In general, expression of
Egr-1 on mRNA level could be veriﬁed on the protein level (Fig. 5A,
B) indicating that Egr-1 expression is regulated at the transcrip-
tional as well as at the translational level similarly. Only those
inhibitors (PTX, Ki16425, and PP2) being effective to suppress
immunoreactive pp42/44 signal (Fig. 3) were also effective to
impair Egr-1 expression on RNA and protein level (Fig. 5A, B).
To conﬁrm that expression of Egr-1 is mediated via the p42/44
MAPK axis, inhibitors of p42/44 and p38 MAPK or SAPK/JNK were
tested. Only PD98059 was effective to impair Egr-1 expression on
mRNA and protein level in response to LPA; SB203580 and the JNK
inhibitor II had no effect (Fig. 5C).
3.5. DNA binding activity of Egr-1
To test Egr-1 at the functional level, MG-63 cells were stimulated
with LPA to induce Egr-1 DNA binding activity. Nuclear proteins
were examined by EMSA using a speciﬁc probe for Egr-1. LPA
stimulation of cells led to a time-dependent increase in Egr-1
binding after 30 min (Fig. 6). Competition experiments with an
excess of non-radiolabelled probe conﬁrmed the identity and
speciﬁcity of the EMSA band. These experiments led us to conclude
that LPA induced an increased binding of Egr-1 to the promotor
region of target genes in MG-63 cells.
3.6. Involvement of LPA1 in LPA-induced suppression of periostin is
mediated by Egr-1
Next, expression of periostin, a protein known to be involved in
both cancer-related events and osteogenic processes [36,37] was
investigated. Under non-stimulated conditions, periostin is abun-
dantly expressed in MG-63 cells (Fig. 7A). However, time-
dependent stimulation of MG-63 cells with LPA led to a dramatic
decrease of periostin after 6 h. Only trace amounts of periostinwere
found in between 12 and 48 h after LPA treatment.
To reveal whether LPA1, the most widely expressed LPA receptor
subtype [7], is involved in downregulation of periostin, cells were
Fig. 6. DNA-binding activity of the transcription factor Egr-1 in LPA-treated human
MG-63 cells: conﬂuent cells were stimulated with LPA (20 mM) at indicated time
periods and nuclear protein extracts were prepared and analysed by EMSA as
described under Materials and methods. Speciﬁcity of the binding pattern was
determined by competition with excess unlabelled oligonucleotides (oligos). Nucleo-
tide sequences of the oligonucleotides used are listed in methods.
Fig. 7. (A) Western blot of LPA-stimulated periostin in human MG-63 cells in the
absence or presence of (un)speciﬁc siRNA for Egr-1: (A) time dependent decrease of
periostin levels after stimulation of MG-63 cells in medium with 20 mM LPA. (B) Cells
were transfected with siRNA speciﬁc for LPA1 (si-LPA1) and (C) with siRNA for Egr-1
(si-Egr-1) or with a scrambled negative control siRNA (si-scr) as described in
Materials and methods. MG-63 cells were stimulated with 20 mM LPA for 2 h (C, Egr-1
[upper panel]) or 12 h (periostin, B and C [lower panel]), respectively; (blank ¼ non
stimulated cells; control ¼ cells stimulated with 20 mM LPA). Cells were lysed, aliquots
of protein lysates were subjected to SDS-PAGE and transferred to nitrocellulose as
described in Materials and methods. Rabbit polyclonal anti-Egr-1, anti-b-actin or rabbit
polyclonal anti-periostin (recognizing an immunoreactive 90 kD band) were used as
primary antibodies (all used at dilutions of 1:1000).
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speciﬁc siRNA reversed the effect of LPA on periostin suppression
(Fig. 7B).
The next set of experiments aimed to reveal a possible cross-
link between LPA-induced upregulation of Egr-1 and suppression
of periostin. Using a highly speciﬁc siRNA for Egr-1 which sup-
pressed LPA-induced expression of Egr-1 but prevented LPA-
stimulated downregulation of periostin, the involvement of the
transcription factor Egr-1 in periostin metabolism is demonstrated
(Fig. 7C).4. Discussion
LPA, an important signalling molecule, exerts its effects by
speciﬁc binding to G-protein coupled receptors [38]. In MG-63,
a human osteogenic sarcoma cell line [39], LPA enhances ﬁbro-
nectin binding to adherent cells [40] and stimulates ﬁbronectin
matrix assembly through a Rho-dependent pathway [41]. Stimu-
lation of MG-63 cells with LPA leads to Gai-dependent stress ﬁbre
formation, activation of the MAPK cascade [42,43], increased
proliferation [44] and osteoblast maturation in conjunction to the
Vitamin D metabolite 1a, 25(OH)2D3 [45]. Expression of LPA1 and
LPA2 has been reported in MG-63 cells [43,44,46] and Gai-coupling
of both receptors is apparently responsible for LPA-mediated
phosphorylation of p42/44 MAPK. We now show expression of
additional LPA receptor transcripts, namely another member of the
Edg family (LPA3) and two members of the non-Edg family of G-
protein coupled receptors (LPA4/5) (Fig. 1). As these LPA receptors
may couple via Gaq and Ga12/13 [16,47,48] we tested whether LPA-
induced signalling pathway(s) leading to p42/44 MAPK activation
is strictly related to Gai- or if Gaq- and/or Ga12/13-mediated signal-
ling is involved.LPA induces osteoblastic differentiation and a lack of LPA1 or its
inhibition by Ki16425 results in abnormal bone development [49]
or completely abrogates osteogenesis [50]. Stimulation with
speciﬁc agonists for the Edg family of G-protein coupled receptor
(LPA1eLPA3) led to activation of p42/44 MAPK and demonstrates
functional coupling of these receptor subtypes. Most importantly,
p42/44 MAPK activation was inhibited by Ki16425 a subtype
selective antagonist for members of the Edg family of G-protein
coupled receptors in the following order: LPA1  LPA3 » LPA2 [35].
As LPA-induced phosphorylation of p42/44 MAPK was completely
suppressed by PTX (Fig. 3A), it is likely that LPA1e3 are functionally
coupled to the Gai-subtype of G-proteins with no involvement of
Gaq and Ga12/13 [43]. Due to the lack of speciﬁc agonists for
members of the non-Edg family (LPA4/LPA5), activation of the p42/
44 MAPK signalling via these receptors was not investigated. LPA4,
recently reported to inhibit osteogenesis [50], might also be
involved in stimulation of theMAPK cascade due to Gai coupling. By
now LPA5 is described to couple Gaq and Ga12/13 [16], so it is unlikely
that this receptor subtype participates in LPA-induced p42/44
MAPK signalling in MG-63 cells.
We show that downstream of Gai the Src family of protein
tyrosine kinases, but not Ras, is required to phosphorylate p42/44
MAPK in response to LPA. A similar signalling route has been
proposed for nontransformed murine osteoblast-like MC3T3-E1
cells [51]. In contrast to MC3T3-E1 cells, MG-63 osteosarcoma cells
exhibited no involvement of Gaq and PKC-mediated induction of
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GTPases, as shown in ovarian theca cells [52] or cdc42 and Rac,
could be observed in MG-63 cells.
The transcription factor Egr-1 is a regulator for activation of
several genes involved in cell proliferation and a role in growth
control was proposed as Egr-1 expression and gene transcription
was observed in many cell types stimulated with mitogens
[53e56]. Egr-1 has also been connected with the development
of cancer, as high Egr-1 levels have been found in a majority
of prostate cancer [57]. Support for its role in cancer comes from
animal models where prostate cancer was impaired in egr-1/
mice [58]. Moreover, Egr-1 is suggested to play a role in multistage
carcinogenesis in skin [59]. Egr-1 also was described to be involved
in growth factor synthesis, e.g. PDGFa/b, insulin-like growth factor
II and transforming growth factor-b1; this interaction might
represent an autocrine loop as PDGF, via its cognate receptor, can
stimulate Egr-1 expression [60e62]. In human U2OS osteosarcoma
cells, Egr-1 was shown to be involved in the upregulation of EGFR in
response to hypoxia, a condition which might cause enhanced cell
proliferation by sensitizing cells upon stimulation with EGF [26].
Here, expression of EGFR, PDGFRa/b on mRNA and protein levels
was followed in response to LPA, however, no changes in expres-
sion of these growth factor receptors have been observed in MG-63
cells within 6 h of stimulation.
As Egr-1 is assumed to play a role in bone formation [22,63,64]
MAPK-dependent expression of Egr-1 in response to LPA was
investigated in MG-63 cells. Following LPA-induced expression of
Egr-1 on mRNA and protein level, a rapid and transient synthesis of
Egr-1, dependent on Gai and phosphorylation of p42/44 MAPK, was
observed. A similar pathway has recently been addressed in rat
mesangial cells [21]. Involvement of the Src family of protein
tyrosine kinases leading to MAPK activation and Egr-1 expression
was also shown in rat osteosarcoma cells in a stimulated micro-
gravity model [65]. We therefore assume that Egr-1 might play an
important role in the proliferative action of LPA in MG-63 cells. In
contrast to Egr-1, LPA was without effect on expression of c-Myc,
a proto-oncogene. C-Myc may be abundantly expressed in human
osteosarcoma [4] and is assumed to be upregulated in MG-63 cells
after treatment with PDGF, forskolin and 12-O-tetradecanoyl-
phorbol-13-acetate [66].
Egr-1 is suggested to be involved in an array of cellular events
during cancer development. Therefore, the present study repre-
sents a basis for Egr-1-mediated regulation of relevant target genes
in cancer initiation and development [67]. A protein assumed to
play a key role in tumour growth and survival, angiogenesis and
invasion of cancer cells is periostin [37]. This 90 kDa adhesion
molecule, originally named osteoblast-speciﬁc factor-2, was ﬁrst
identiﬁed in bone, and implicated in regulating adhesion and
differentiation of osteoblasts [36]. LPA-induced expression of per-
iostin has been reported in stromal cells [68] and a recent report
addressed the role of the LPAeLPA1 axis in periostin formation in
human adipose tissue-derived mesenchymal stem cells [69].
Different expression patterns of periostin on mRNA and protein
level have been reported in various human osteosarcoma cell lines
(e.g. MHM, KPDXM and Eggen) and expression of periostin mRNA
was inversely related to the cell’s abilities to differentiate and
mineralize [70]. In human U2OS osteosarcoma cells knock down of
periostin reduced entry into S-phase, migration, proliferation and
invasion [71].
Previous studies have shown that in TNFa-stimulated chon-
drocytes inhibition of various extracellular matrix genes is directly
related to binding of Egr-1 to speciﬁc regions in the promoter [67].
Our data demonstrate that periostin is abundantly expressed in
human MG-63 osteosarcoma cells. Stimulation of cells with LPA
resulted in a decrease of periostin that was strictly dependent onEgr-1 expression levels. Whether this effect is mediated by binding
of this transcription factor to a speciﬁc Egr-1 response element in
the promotor region (925e941 bps upstream of the transcription
site) of the periostin gene is currently under investigation.
Taken together, our ﬁndings demonstrate expression of LPA
receptor subtypes 1e5 in human MG-63 osteosarcoma cells and
functional coupling of LPA1e3 using receptor subtype speciﬁc
agonists. LPA induced a rapid and transient synthesis of Egr-1 that is
strictly mediated via Gai/Src/p42/44 MAPK pathway with no
involvement of the Gaq/11/PLC/PKC or the PLD/PI3 kinase/Akt
pathways. Most importantly, we here show that the LPA-LPA1-Egr-1
axis is tightly coupled with the expression of periostin.
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